Steven Daniel Schwartz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 16,875 shares at $38.16 ($648K) on 2015-05-22, disclosed to the SEC on 2015-05-22.
Scheduled sale ($648k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.16 | 11,679 | $446K | 68.8% |
| 2 | $38.88 | 5,196 | $202K | 31.2% |
| Total | $38.38 avg | 16,875 | $648K | 100% |
| Filing → |
| AAVL | SELL | 2015-05-11 | $570K | — | Filing → |
| AAVL | SELL | 2015-04-23 | $652K | — | Filing → |
| AAVL | SELL | 2015-04-13 | $685K | — | Filing → |